HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Avidities of IgG directed against viral capsid antigen or early antigen: useful markers for significant Epstein-Barr virus serology.

Abstract
Classical Epstein-Barr virus (EBV) serology can be misleading in some cases due to the variability of the viral capsid antigen (VCA)-IgM response, persistent or reactivated VCA-IgM, or loss of anti-EBNA-1 during suppression of the cellular immune system. Therefore, we studied the usefulness and significance of avidity determinations of VCA-IgG and EA-IgG to achieve unequivocal interpretation of serological results. Avidities of EBV capsid antigen-specific IgG (VCA-IgG) and early antigen-specific IgG (EA-IgG) were determined by indirect immunofluorescence during and after acute EBV infection. Low-avidity antibodies were removed from antigen-antibody complexes by incubation with 6 M urea for 3 minutes. The analysis of 105 sera taken at defined time spans with regard to the onset of clinical symptoms allowed us to determine the kinetics of maturation of avidity of VCA-IgG. All sera had low-avidity antibodies at the onset of disease. More than 90% of the sera showed an avidity index below 0.25 during the first 10 days after the onset of disease. Fifty percent of the sera exhibited an avidity index of 0.25 or above 20-30 days after the onset of clinical symptoms. Sera from past infections uniformly exhibited avidity indices of 0.5 or 1. Avidity of EA-IgG may still be low when avidity of VCA-IgG is already borderline or high, thus allowing further differentiation of acute and recent infections. Avidity determination represents an important additional marker of serology in classical cases and allows diagnosis in aberrant cases, such as acute infections with low or undetectable VCA-IgM.(ABSTRACT TRUNCATED AT 250 WORDS)
AuthorsA Andersson, V Vetter, L Kreutzer, G Bauer
JournalJournal of medical virology (J Med Virol) Vol. 43 Issue 3 Pg. 238-44 (Jul 1994) ISSN: 0146-6615 [Print] United States
PMID7931184 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References
  • Antigens, Viral
  • Biomarkers
  • Capsid Proteins
  • DNA-Binding Proteins
  • Epstein-Barr Virus Nuclear Antigens
  • Epstein-Barr viral capsid antigen
  • Epstein-Barr virus early antigen
  • Immunoglobulin G
  • Immunoglobulin M
Topics
  • Acute Disease
  • Adolescent
  • Adult
  • Antibody Affinity
  • Antigens, Viral
  • Biomarkers
  • Capsid Proteins
  • Child
  • Child, Preschool
  • DNA-Binding Proteins
  • Epstein-Barr Virus Nuclear Antigens
  • Herpesvirus 4, Human (immunology)
  • Humans
  • Immunoglobulin G (blood)
  • Immunoglobulin M (blood)
  • Infant
  • Infectious Mononucleosis (diagnosis, immunology)
  • Kinetics
  • Serologic Tests

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: